La realidad asistencial del tratamiento del mieloma múltiple de alto riesgo en España
Hernández-Rivas, José-Ángel; Gironella Mesa, Mercedes.
Med. clín (Ed. impr.)
; 154(8): 315-319, abr. 2020. graf
Artículo en Español | IBECS (España) | ID: ibc-193203
Documentos relacionados
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis.
Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma.
Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy.
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study.
Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy.
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment.
The Association Between the Urine Protein-to-Albumin Gap and the Diagnosis of Multiple Myeloma: A Population-Based Retrospective Cohort Study.
Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.
Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020-2025.
Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments.